Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21868839 | 0.87 | ESR1 (0.33) | ESR1ESR2ARRIPK1 | |
| SCHEMBL22024010 | 0.81 | KCNN4 (0.40) | ESR1ESR2RIPK1 | |
| SCHEMBL18935517 | 0.80 | ESR1 (0.33) | ESR1ESR2AR | |
| SCHEMBL19251180 | 0.80 | HCAR2 (0.31) | ESR1ESR2 | |
| SCHEMBL21164691 | 0.79 | ESR1 (0.46) | ESR1ESR2ARRIPK1 | |
| SCHEMBL20288417 | 0.78 | CNR2 (0.33) | ESR1ESR2ARRIPK1 | |
| SCHEMBL22224487 | 0.77 | ESR1 (0.41) | ESR1ESR2AR | |
| SCHEMBL21761171 | 0.76 | CNR2 (0.42) | ESR1ESR2 | |
| SCHEMBL18929881 | 0.76 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL14540294 | 0.75 | ESR1 (0.57) | ESR1ESR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, BCL2, AIFM1 | ESR1 4143/4885ESR2 2249/4885AR 3267/4885 |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, BCL2, AIFM1 | ESR1 4143/4885ESR2 2249/4885AR 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.